{"id":70747,"date":"2026-05-12T10:39:40","date_gmt":"2026-05-12T10:39:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70747"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"cagrilintide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/cagrilintide\/","title":{"rendered":"Cagrilintide"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Cagrilintid?<\/h3>\n

Cagrilintide<\/strong> (v\u00fdvojov\u00fd k\u00f3d AM833) je 37-aminokyselinov\u00fd dlouho p\u016fsob\u00edc\u00ed syntetick\u00fd analog amylinu vyvinut\u00fd spole\u010dnost\u00ed Novo Nordisk. Jedn\u00e1 se o hlavn\u00ed v\u00fdzkumn\u00fd peptid t\u0159\u00eddy amylinu v sou\u010dasn\u00e9m metabolick\u00e9m v\u00fdzkumu a partnerskou slou\u010deninu v kombinaci CagriSema (cagrilintid + semaglutide<\/a>), nyn\u00ed v pokro\u010dil\u00e9 f\u00e1zi 3 klinick\u00fdch studi\u00ed pro obezitu a diabetes 2. typu. Polo\u010das v plazm\u011b ~159 hodin umo\u017e\u0148uje pod\u00e1v\u00e1n\u00ed jednou t\u00fddn\u011b. Dod\u00e1v\u00e1 se v lyofilizovan\u00fdch vial\u00e1ch o obsahu 5 mg a 10 mg pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS \u010d\u00edslo<\/strong><\/td>\n1415456-99-3 (cagrilintid; b\u011b\u017en\u011b uv\u00e1d\u011bno)<\/td>\n<\/tr>\n
Typ<\/strong><\/td>\nDlouhodob\u011b p\u016fsob\u00edc\u00ed syntetick\u00fd analog amylinu (acylovan\u00fd 37-aminokyselinov\u00fd peptid; agonista receptoru pro kalcitonin\/amylin; v\u00fdvojov\u00fd k\u00f3d AM833 spole\u010dnosti Novo Nordisk)<\/td>\n<\/tr>\n
item7<\/strong><\/td>\n~4 981 Da (s acylac\u00ed C20 mastnou dikarboxylovou kyselinou a intramolekul\u00e1rn\u00edm disulfidov\u00fdm m\u016fstkem)<\/td>\n<\/tr>\n
Struktura<\/strong><\/td>\n37 aminokyselin zalo\u017een\u00fdch na lidsk\u00e9m amylinov\u00e9m skeletu s substitucemi sni\u017euj\u00edc\u00edmi tvorbu amyloidn\u00edch agreg\u00e1t\u016f, intramolekul\u00e1rn\u00edm disulfidov\u00fdm m\u016fstkem Cys2\u2013Cys7 nezbytn\u00fdm pro vazbu na receptor a C20 mastnou dikarboxylovou kyselinou p\u0159ipojenou p\u0159es \u03b3-Glu-OEG-OEG spacer, kter\u00fd zaji\u0161\u0165uje silnou reverzibiln\u00ed vazbu na s\u00e9rov\u00fd albumin pro t\u00fddenn\u00ed polo\u010das. C-konec amidov\u00e1n.<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd pr\u00e1\u0161ek (b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd)<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nBakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed. Acylovan\u00e9 peptidy se mohou rozpou\u0161t\u011bt pomaleji ne\u017e men\u0161\u00ed neupraven\u00e9 peptidy \u2014 ponechte del\u0161\u00ed \u010das pro rovnov\u00e1hu.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Co je Cagrilintid?<\/h2>\n

Cagrilintide<\/strong> je dlouhodob\u011b p\u016fsob\u00edc\u00ed syntetick\u00fd analog amylinu \u2014 37-aminokyselinov\u00e9ho pankreatick\u00e9ho peptidov\u00e9ho hormonu, kter\u00fd je spolu s inzulinem secernov\u00e1n z beta bun\u011bk a pat\u0159\u00ed mezi hlavn\u00ed endogenn\u00ed regul\u00e1tory postprandi\u00e1ln\u00ed gluk\u00f3zov\u00e9 exkurze, sign\u00e1l\u016f sytosti a vyprazd\u0148ov\u00e1n\u00ed \u017ealudku. Endogenn\u00ed lidsk\u00fd amylin m\u00e1 kr\u00e1tk\u00fd plazmatick\u00fd polo\u010das (~13 minut), \u0161patnou farmakokinetiku a siln\u00fd sklon k tvorb\u011b amyloidn\u00edch agreg\u00e1t\u016f (stejn\u00fd amyloid, kter\u00fd se hromad\u00ed v pankreatick\u00e9 tk\u00e1ni u diabetu 2. typu). Cagrilintid byl vyvinut spole\u010dnost\u00ed Novo Nordisk (v\u00fdvojov\u00fd k\u00f3d AM833) k p\u0159ekon\u00e1n\u00ed t\u011bchto limitac\u00ed: substituce sni\u017euj\u00edc\u00ed agregaci, zachovan\u00fd intramolekul\u00e1rn\u00ed disulfidov\u00fd m\u016fstek pro vazbu na receptor a C20 mastn\u00e1 dikarboxylov\u00e1 kyselina p\u0159ipojen\u00e1 p\u0159es \u03b3-Glu-OEG-OEG spacer, kter\u00e1 zaji\u0161\u0165uje silnou reverzibiln\u00ed vazbu na cirkuluj\u00edc\u00ed s\u00e9rov\u00fd albumin. Kombinovan\u00fd efekt vede k plazmatick\u00e9mu polo\u010dasu p\u0159ibli\u017en\u011b 159 hodin (~6,5 dne), co\u017e umo\u017e\u0148uje t\u00fddenn\u00ed subkut\u00e1nn\u00ed v\u00fdzkumn\u00e9 d\u00e1vkov\u00e1n\u00ed.<\/p>\n

Cagrilintid m\u00e1 molekulovou hmotnost p\u0159ibli\u017en\u011b 4 981 Da v\u010detn\u011b acylov\u00e9ho \u0159et\u011bzce a disulfidov\u00e9ho m\u016fstku. Intramolekul\u00e1rn\u00ed disulfidov\u00fd m\u016fstek Cys2\u2013Cys7 je nezbytn\u00fd pro vazbu na receptor \u2014 redukce t\u00e9to vazby p\u0159em\u011bn\u00ed peptid na neaktivn\u00ed line\u00e1rn\u00ed formu. Mastn\u00e1 kyselina je o jeden uhl\u00edk del\u0161\u00ed ne\u017e C18 acylov\u00fd \u0159et\u011bzec semaglutidu, co\u017e vede k dlouh\u00e9mu polo\u010dasu prost\u0159ednictv\u00edm stejn\u00e9ho mechanismu vazby na albumin. Cagrilintid je nejpokro\u010dilej\u0161\u00ed slou\u010deninou v nov\u00e9 vln\u011b farmakologie amylinov\u00e9 dr\u00e1hy, s hlavn\u00edm klinick\u00fdm programem kombinace CagriSema<\/strong> \u2014 cagrilintid 2,4 mg + semaglutide<\/a> 2,4 mg t\u00fddn\u011b \u2014 kter\u00e1 dokon\u010dila f\u00e1zi 3 klinick\u00fdch studi\u00ed REDEFINE-1 (obezita) a REDEFINE-2 (T2DM) s redukc\u00ed t\u011blesn\u00e9 hmotnosti p\u0159ibli\u017en\u011b 20\u201323 % za 68 t\u00fddn\u016f. Cagrilintid nen\u00ed FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem schv\u00e1len pro hum\u00e1nn\u00ed terapeutick\u00e9 pou\u017eit\u00ed jako samostatn\u00fd prost\u0159edek nebo v kombinaci. V\u00fdzkumn\u00fd cagrilintid prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro lidsk\u00e9 ani veterin\u00e1rn\u00ed pod\u00e1v\u00e1n\u00ed.<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 agonismus amylinov\u00e9ho receptoru v CNS a perifern\u00edch m\u00edstech<\/h2>\n

Co \u010din\u00ed cagrilintid farmakologicky odli\u0161n\u00fdm od agonist\u016f GLP-1, je jeho p\u016fsoben\u00ed na zcela odli\u0161n\u00fd receptorov\u00fd syst\u00e9m \u2014 rodinu receptor\u016f pro amylin\/kalcitonin \u2014 prost\u0159ednictv\u00edm t\u0159\u00ed hlavn\u00edch mechanism\u016f<\/strong> dokumentovan\u00fdch v publikovan\u00e9m v\u00fdzkumu:<\/p>\n